Searched for
GLAND PHARMA LISTING
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- NSE clarifies non-entry of Castrol, Gland Pharma in F&O. Check other stock inclusionsThis announcement comes after a previous decision to add six companies to the F&O segment, namely Castrol India, Gland Pharma, NBCC, Phoeni...
- Fosun is said to plan block deals to pare stake in Gland PharmaThe listed arm of billionaire Guo Guangchang’s Fosun International Ltd. holds about 58% of Gland Pharma, which has a market value 303 billi...
- Fosun taps big buyout funds for Gland PharmaBuyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are among those...
- Hot Stocks: Brokerage view on Gland Pharma, Aditya Birla Fashion and PDSThe deal appears complementary to Gland in terms of EU market access, branded pharma customer base and some technologies, the brokerage sai...
- Fosun Said to Mull Sale of India’s $3.6 Billion Gland PharmaA sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...
- Gland Pharma rallies 9% as Fosun mulls selling controlling stake in firmA sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International h...
- View: Covid-19 and China are the two challenges India is struggling withIncidentally, India’s biggest pharma initial public offering capitalised on both these aspects. Last month, a Hyderabad based injectables c...
- Gland Pharma lists at 14% premium over issue priceThe IPO, which was sold between November 9 and 11, was subscribed 2.06 times in a three-day bidding process, with the HNI and retail quotas...
- Gland Pharma in high demand ahead of listingGland Pharma shares were available at a premium of Rs 20 in the grey market during the offer subscription period between Nov 9 and 11. The ...
- Stocks in the news: Gland Pharma, LVB, Vodafone Idea, Mphasis & L&TMphasis Consulting has acquired UK-based Datalytyx for up to 13.3 million pounds (about Rs 130.4 crore).
- Gland Pharma IPO: Analysts recommend subscribing, but flag stretched valuationsGland Pharma’s IPO is India’s largest pharmaceutical IPO ever.
- Gland Pharma IPO: Issue date, price band & other key detailsThe drugmarker will likely announce the name of anchor investors by the end of Friday.
- Grey market premium fizzles out for Gland Pharma after fixing price bandThe Gland Pharma IPO, India’s largest from the pharmaceutical sector, comprises a fresh issue aggregating up to Rs 1,250 crore and an offer...
- Even before IPO details are out, Gland Pharma buzzing in grey marketThe pharma company is eyeing to hit the bourses with a Rs 6,000 crore issue, which will make it the biggest IPO from the Indian pharma sect...
- Gland Pharma seeks lock-in exemption for shares owned by Ex Satyam CEO Ramanlinga RajuAs per market Sebi rules, all the pre-IPO capital needs to be locked in for a period of one year. However, it is not feasible to put the sh...
- 74% Chinese-owned Hyderabad pharma firm files for IPOThe fresh issue and the offer for sale together is expected to take the IPO size to around Rs 3,000 crore.
- Chinese firm-backed Gland Pharma files for IPO; may raise up to Rs 6,000 croreThe company may raise up to $800 million or Rs 6,000 crore, a source with the knowledge of the matter said.
- KKR set to pick up 35% stake in Gland Pharma for about Rs 1,300 croreThe two-part transaction, likely to be announced this week, is a combination of fresh equity infusion and a buyout of Evolvance India Life ...
Load More
